However, RIPOR2 was expressed at significantly higher levels in normal tissues than tumor tissues in patients with bladder urothelial carcinoma, breast invasive carcinoma, CC, colon adenocarcinoma (COAD), glioblastoma (GBM), kidney chromophobe, liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma, prostate adenocarcinoma, rectum adenocarcinoma (READ), and uterine corpus endometrial carcinoma (UCEC). This evidence concerns the gene RIPOR2 and bladder transitional cell carcinoma.